Please assess the completion status of the following clinical trial:

Trial Title: A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Active subfoveal choroidal neovascular (CNV) lesion or juxtafoveal lesion secondary to age-related macular AMD~* An ETDRS BCVA score between 60 and 25 (inclusive) letters~Exclusion Criteria:~* Previous treatment for wet AMD or previous treatment for CNV due to other causes in the Study Eye~* Clinically significant ocular disorders which may interfere with assessment of visual acuity, assessment of toxicity, or fundus photography in the Study Eye~* Poorly controlled diabetes mellitus (defined as HbA1c\>7%)~* Any clinically significant cardiovascular, renal or hepatic conditions, recent surgery, or malignancy, that would make the participant unsuitable for the study

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 0.5 mg ranibizumab with 2.0 mg OPT-302 (Type: EXPERIMENTAL): 0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by 2.0 mg OPT-302 intravitreal injection (0.05 ml)
- 0.5 mg ranibizumab with 0.5 mg OPT-302 (Type: EXPERIMENTAL): 0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by 0.5 mg OPT-302 intravitreal injection (0.05 ml)
- 0.5 mg ranibizumab with sham (Type: SHAM_COMPARATOR): 0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by sham

Based on this trial design, predict the completion outcome and termination type (if applicable).